Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Firefly Neuroscience (AIFF) EBT Margin (2016 - 2025)

Historic EBT Margin for Firefly Neuroscience (AIFF) over the last 15 years, with Q3 2025 value amounting to 680.15%.

  • Firefly Neuroscience's EBT Margin rose 123168200.0% to 680.15% in Q3 2025 from the same period last year, while for Sep 2025 it was 3137.93%, marking a year-over-year increase of 73364000.0%. This contributed to the annual value of 522.49% for FY2023, which is 4726500.0% down from last year.
  • Per Firefly Neuroscience's latest filing, its EBT Margin stood at 680.15% for Q3 2025, which was up 123168200.0% from 611.71% recorded in Q2 2025.
  • Firefly Neuroscience's EBT Margin's 5-year high stood at 6878.18% during Q4 2024, with a 5-year trough of 30069.77% in Q1 2025.
  • For the 5-year period, Firefly Neuroscience's EBT Margin averaged around 3593.26%, with its median value being 56.61% (2022).
  • In the last 5 years, Firefly Neuroscience's EBT Margin surged by 125413400bps in 2024 and then tumbled by -207197700bps in 2025.
  • Firefly Neuroscience's EBT Margin (Quarter) stood at 93.75% in 2021, then surged by 44bps to 52.34% in 2022, then crashed by -10720bps to 5663.16% in 2023, then soared by 221bps to 6878.18% in 2024, then plummeted by -110bps to 680.15% in 2025.
  • Its EBT Margin stands at 680.15% for Q3 2025, versus 611.71% for Q2 2025 and 30069.77% for Q1 2025.